Vor Bio Licenses RC298 From RemeGen
The Boston biotech is paying $10 million in cash plus warrants valued at about $46 million for rights outside Greater China.
Updated on Nov. 12, 2026 in Biotech

Vor Bio has licensed RC298 from RemeGen for $10 million upfront in cash and warrants valued at approximately $46 million. The license covers rights to the drug candidate outside Greater China.
Why it matters
The deal extends Vor Bio's ties to RemeGen, which it also licensed telitacicept from last year for $45 million upfront. It shows how Western biotechs are sourcing early-stage assets from Chinese developers.
RC298 is in IND-enabling development, with RemeGen leading preclinical and phase 1 work in China before Vor takes over later trials and commercialization outside Greater China. RemeGen could receive up to $300 million in development milestones, including a $20 million payment tied to initial clinical goals, though the stub does not describe the technical profile of the molecule.
The players
Vor Bio
Vor Bio is a Boston-based biotechnology company developing therapies for immune-mediated diseases, having pursued strategic alternatives before its recent in-licensing deals.
RemeGen
RemeGen is a Chinese biopharmaceutical company that develops novel biologic drugs and has licensed several candidates to Western partners.
The details
Vor Bio will pay RemeGen $10 million in cash and issue pre-funded warrants for 2.3 million Vor shares, valued at roughly $46 million based on Vor's Nov. 11 closing price. RemeGen will run early development in China, and Vor expects an investigational new drug application to be submitted there in the first half of 2027.
Timeline
2025: Vor licensed telitacicept from RemeGen for $45 million upfront.
Nov. 11, 2026: Closing share price used to value the warrants.
Nov. 12, 2026: Announcement of the RC298 licensing deal.
First half of 2027: Expected RC298 investigational new drug application in China.
Tech Race
The RC298 license follows Vor Bio's 2025 telitacicept deal with RemeGen, which was $45 million upfront, and extends the same partnership to a second asset. Together the two transactions show Vor relying on a single Chinese developer for its in-licensed pipeline after cutting 95% of its staff.
For patients, the deal changes nothing immediately, since RC298 is still in preclinical development with no clinical trial results yet. Its eventual availability would depend on phase 1 results and regulatory approval in each market.
The takeaway
Licensing deals like this one let smaller Western biotechs add pipeline assets without building early research in-house, but they also tie a company's prospects to partners abroad. Readers tracking the sector can watch whether RC298 reaches its China IND filing on the expected 2027 timeline.
Further reading
For broader context on drug development deals, see Biotech.



